Navigation Links
Sensor biochips could aid in cancer diagnosis and treatment
Date:10/21/2009

tem could be used in the treatment of inoperable tumors, for example pancreatic tumors.

In the past, microchips have also been developed at the TUM's Heinz Nixdorf Chair for use in other research fields. For example, one such system is used in the analysis of the water quality of streams and rivers. In this case, a small pump removes samples at regular intervals from the water body and channels it via a pipe to a sensor chip on which algae have been planted. As algae are highly sensitive to toxic substances, they are particularly suitable for water analysis and react to the minutest impurities: their metabolic activity, which is measured on the basis of their oxygen production, declines in less than one minute in the presence of toxins. The data recorded by this sensor system are transmitted via mobile telephone to a computer that raises the alarm. The TUM research team won the E.ON Environmental Award, presented by the Bavarian energy company of the same name, for this system in 2008.


'/>"/>

Contact: Markus Bernards
presse@zv.tum.de
49-892-892-2562
Technische Universitaet Muenchen
Source:Eurekalert  

1

GOOD

Page: 1 2 3

Related biology news :

1. Panasonic Offers U.are.U(R) Fingerprint Sensor From DigitalPersona on Stingray JS-950 Point-of-Sale Workstations
2. NCR Embeds DigitalPersona U.are.U(R) 4500HD Fingerprint Sensor in New NCR RealPOS(TM) 70XRT Point-of-Sale Workstations
3. HAMILTON Unveils ARC Sensor Technology
4. Think zinc: Molecular sensor could reveal zincs role in diseases
5. SRNL, automakers to develop high-performance wireless sensors networks
6. PRS And EmSense Partner To Integrate Bio-Sensory Measures In Packaging Research Studies
7. New way to make sensors that detect toxic chemicals
8. Fate in fly sensory organ precursor cells could explain human immune disorder
9. Toward cheap underwater sensor nets
10. Uncooperative voltage sensors
11. Sensoring the World Wide Web

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sensor biochips could aid in cancer diagnosis and treatment
Sensor biochips could aid in cancer diagnosis and treatment
(Date:11/20/2009)...s are at work on many scientific and technological...cently provided support that totals nearly $4.3 mi...estigators under the American Recovery and Reinves...n awarded grants for investigation of solar phenom...hysics, will enhance the capabilities of NJIT,s Bi...
(Date:11/20/2009)...nvited to contribute their abstracts to the World ...the largest global meeting devoted to all aspects ...tient care. The Congress will be held in Florence,...stracts can be submitted online at http://www.iof...ebruary 4, 2010. , IOF and ESCEO are pleased to ...
(Date:11/20/2009)...tion of a single bacterial gene into yeast, resear...etherlands achieved three improvements in bioethan...ore ethanol, less acetate and elimination of the m...was published in the scientific journal Applied a... Bioethanol is made by the yeast Saccharomyces cer...
Breaking Biology News(10 mins):NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Delft breakthrough in bioethanol production from agricultural waste 2Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 1Image Sensors 2009 Announces Final Program and New Interactive Brochure 52852 2Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 1Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 2Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 3Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 4Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 5Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO 01 Trial in Secondary Progressive Multiple Sclerosis 4785 6Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 1Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 2Many Heart Attack Patients Not Referred to Cardiac Rehab 52843 3
...ein secreted by mussels and a polymer that repels ...iversity have designed a versatile new two-sided c...ts. , Currently the longevity of certain medical ...ins in the body gradually accumulate on the device...ce and threatening patients with infections. Unfor...
...adly form of skin cancer very resistant to treatme...mp; Research Institute and the University of South...prompts the immune system to aid in the fight agai...al trial because it is the first time that electro... gene therapy study in humans," said Richard Helle...
...from Columbia University Medical Center have shown...bris from blocked arteries during a heart attack d..., called distal microcirculatory protection, is co... vein grafts and stenting in carotid arteries. The...nal of the American Medical Association, found tha...
Other Biology News:Innovative coating could give medical implants a longer life 2Researchers test new therapy for advanced melanoma 2Columbia study shows widely used artery clearing device does not help patients during heart attack 2
(Date:11/19/2009)...ike to be able to charge their cell phones and oth... A recent discovery made by UC San Diego engineers...rs that could do just this. , In recent researc...ar Bandaru, a professor in the UCSD Department of ...raduate student Mark Hoefer, have found that artif...
(Date:11/19/2009)...Y., Nov. 19 Dr. Mate Hidvegi, inve...nds to a press release issued on November 17 by Bi...or making false and self-serving statements about ...r. Hidvegi stated from his office in Budapest, Hun...n Avemar does not apply to AveULTRA, www.aveultr...
(Date:11/19/2009)...., Nov. 19 Spherix Incor...ology for diabetes therapy, and a provider of tech...supplement, biotechnology and pharmaceutical compa...ual Meeting of Shareholders. ,, At the meeting,...EX ) elected the following members to the Board of...
(Date:11/19/2009)...v. 19 /PRNewswire/ - Aegera Therapeutics Inc. anno...andomized Phase 2B study of AEG35156, a targeted a...multiple oncology indications. ,, The study, en...the X-Linked Inhibitor of Apoptosis (XIAP) Antisen...tarabine and Idarubicin in AML Following Failure o...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...e-FirstCall/ - Oncothyreon Inc. (NASDAQ:,ONTY) (TS...zation plan to,focus the Company,s resources on th... process development and manufacturing of Stimuvax...linical development of PX-12,beyond the ongoing tr...ntrate Oncothyreon,s efforts and available resourc...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced t...nt in a Phase 1 trial of CVT-3619, a novel oral co...diseases. The U.S. Food and Drug,Administration re...drug,application for CVT-3619, a partial A1 adenos...sess the safety and pharmacokinetic profile,of CVT...
...alidity of Purdue patents; Purdue licenses ...hs, STAMFORD, Conn., Sept. 2 Purdue Pharma L.P. ...Hazelwood, Missouri have,agreed to end the OxyCont...atent infringement lawsuit between them in the Uni...t of New York., According to the agreement, Malli...
Other Biology Technology:Oncothyreon announces prioritization plan for development programs 2Oncothyreon announces prioritization plan for development programs 3Oncothyreon announces prioritization plan for development programs 4Oncothyreon announces prioritization plan for development programs 5CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 2CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 3Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2
Caveolin Sampler Kit from BD Biosciences Pharmingen
UCB Eosinophil Chip-IHC from 3H Biomedical AB
UCB MSC Cell Chip-IHC from 3H Biomedical AB
B Cell Chip-IHC from 3H Biomedical AB
Biology Products: